Previous studies of autologous BM-derived CD133+ cells injected either via intracoronary infusion [32] or intramyocardial injection [33] augmenting vasculogenesis in patients with myocardial ischemia [34] prompted us to investigate the potential of genetically modified stem cells in ischemic heart disease. Here, PROM1 is linked to coronary artery disorder.